世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000028536

薬物乱用検査市場レポート2021−2031

Visiongain

Drugs of Abuse Testing Market Report 2021-2031

発刊日 2020/12/03

言語英語

体裁PDF/290ページ

「PDF」版290ページ

0000028536

薬物乱用検査市場レポート2021−2031
Drugs of Abuse Testing Market Report 2021-2031

3,499 GBP

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※販売価格はシングルユーザーライセンスのものとなります。
※シングルユーザーライセンスのレポートは印刷不可、およびライセンス期間は1年となります。
※印刷可能のレポートをご希望の場合は、デパートメントライセンス(ライセンス期間1年、ユーザー数5人)をご検討ください。
※詳しくはお問い合わせください。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

製品の種類別予測:(アナライザー、迅速検査装置、消耗品、検査サービス)、検体の種類別(唾液、呼気、尿、血液、毛髪、汗、その他)、検査の種類;別(オンサイト・スクリーニング検査、検査室での薬物試験)、薬物の種類別(アルコール、大麻、コカイン、オピオイド、アンフェタミン、LSD、その他)、患者層別(高齢者、成人、小児)、エンドユーザー別(病院、職場&学校、刑事司法制度&法執行機関、診断センター、スポット試験、法医学研究所、専門クリニック、その他)、流通経路別(直接入札、小売)、プラス主要メーカーのプロフィール、地域別、主要国別分析、プラスCOVID-19回復シナリオ

薬物乱用検査市場−動向、研究開発の進歩、売上予測
薬物乱用検査市場はどこへ向かうのでしょうか。Visiongainのレポートはデータ、動向、事業機会、事業見通しについて分析、評価を行い、2031年までの売上予測を示します。

トップの座を維持するために:
250ページを超えるレポートに480以上の表と460以上のグラフを掲載。最も収益が見込まれる分野と今後の市場見通しを明らかにします。世界全体および地域別の各レベルにおける売上を予測することが可能です。成長を続ける薬物乱用検査市場にはまだ多くの事業機会が残っています。

レポート詳細

目次

1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered By This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain

2. Introduction to the Drugs of Abuse Testing Market
2.1. Drugs of Abuse Testing Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Application Submarkets Definitions

3. Drugs of Abuse Testing Market Overview
3.1. Global Drugs of Abuse Testing Market Size and Forecast By Region
3.2. Global Drugs of Abuse Testing Market Share By Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing drugs abuse
3.3.1.2. Increasing prevalence of chronic pain
3.3.1.3. Growing demand for drugs of abuse testing in emerging economies
3.3.1.4. Surging investment in drugs of abuse testing
3.3.1.5. Increasing research and developed activates
3.3.2. Market Restraints
3.3.2.1. High cost of development
3.3.2.2. Stringent regulation associated with product development
3.3.3. Opportunities
3.3.3.1. Government initiative and awareness program
3.3.3.2. Technological advancements and the modernization in addiction treatment
3.3.4. Challenges
3.3.4.1. Less awareness regarding diagnosis and treatment of Drugs of Abuse in developing nations
3.3.4.2. Short shelf life of products
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength
3.3.5.1.2. Strength
3.3.5.1.3. Strength
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness
3.3.5.2.2. Weakness
3.3.5.2.3. Weakness
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity
3.3.5.3.2. Opportunity
3.3.5.3.3. Opportunity
3.3.5.4. Threats
3.3.5.4.1. Threat
3.3.5.4.2. Threat
3.3.5.4.3. Threat
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry

4. Global Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 By Product Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Analyzers
4.1.1.1. Analyzers market size and forecast, 2021-2031 (USD Million)
4.1.2. Rapid Testing Devices
4.1.2.1. Rapid Testing Devices market size and forecast, 2021-2031 (USD Million)
4.1.3. Consumables
4.1.3.1. Consumables market size and forecast, 2021-2031 (USD Million)
4.1.4. Laboratory Services
4.1.4.1. Laboratory Services market size and forecast, 2021-2031 (USD Million)

5. Global Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 By Sample Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Saliva
5.1.1.1. Saliva market size and forecast, 2021-2031 (USD Million)
5.1.2. Breath
5.1.2.1. Breath market size and forecast, 2021-2031 (USD Million)
5.1.3. Urine
5.1.3.1. Urine market size and forecast, 2021-2031 (USD Million)
5.1.4. Blood
5.1.4.1. Blood market size and forecast, 2021-2031 (USD Million)
5.1.5. Hair
5.1.5.1. Hair market size and forecast, 2021-2031 (USD Million)
5.1.6. Sweat
5.1.6.1. Sweat market size and forecast, 2021-2031 (USD Million)
5.1.7. Others
5.1.7.1. Others market size and forecast, 2021-2031 (USD Million)

6. Global Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 By Testing Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Onsite Screening Testing
6.1.1.1. Onsite Screening Testing market size and forecast, 2021-2031 (USD Million)
6.1.2. Laboratory Drug Testing
6.1.2.1. Laboratory Drug Testing market size and forecast, 2021-2031 (USD Million)

7. Global Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 By Drug Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Alcohol
7.1.1.1. Alcohol market size and forecast, 2021-2031 (USD Million)
7.1.2. Cannabis
7.1.2.1. Cannabis market size and forecast, 2021-2031 (USD Million)
7.1.3. Cocaine
7.1.3.1. Cocaine market size and forecast, 2021-2031 (USD Million)
7.1.4. Opioids
7.1.4.1. Opioids market size and forecast, 2021-2031 (USD Million)
7.1.5. Amphetamine
7.1.5.1. Amphetamine market size and forecast, 2021-2031 (USD Million)
7.1.6. LSD
7.1.6.1. LSD market size and forecast, 2021-2031 (USD Million)
7.1.7. Others
7.1.7.1. Others market size and forecast, 2021-2031 (USD Million)

8. Global Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 By Patient Demographics (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.1.1. Geriatric Patient
8.1.1.1. Geriatric Patient market size and forecast, 2021-2031 (USD Million)
8.1.2. Adult Patient
8.1.2.1. Adult Patient market size and forecast, 2021-2031 (USD Million)
8.1.3. Pediatric
8.1.3.1. Pediatric market size and forecast, 2021-2031 (USD Million)

9. Global Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 By End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.1.1. Hospitals
9.1.1.1. Hospitals market size and forecast, 2021-2031 (USD Million)
9.1.2. Workplaces & Schools
9.1.2.1. Workplaces & Schools market size and forecast, 2021-2031 (USD Million)
9.1.3. Specialty Clinics
9.1.3.1. Specialty Clinics market size and forecast, 2021-2031 (USD Million)
9.1.4. Criminal Justice Systems & Law Enforcement Agencies
9.1.4.1. Criminal Justice Systems & Law Enforcement Agencies market size and forecast, 2021-2031 (USD Million)
9.1.5. Diagnostics Laboratories
9.1.5.1. Diagnostics Laboratories market size and forecast, 2021-2031 (USD Million)
9.1.6. On-the-spot Testing
9.1.6.1. On-the-spot Testing market size and forecast, 2021-2031 (USD Million)
9.1.7. Forensic Laboratories
9.1.7.1. Forensic Laboratories market size and forecast, 2021-2031 (USD Million)
9.1.8. Others
9.1.8.1. Others market size and forecast, 2021-2031 (USD Million)

10. Global Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 By Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.1.1. Direct Tender
10.1.1.1. Direct Tender Market size and forecast, 2021-2031 (USD Million)
10.1.2. Retail Sales
10.1.2.1. Retail Sales Market size and forecast, 2021-2031 (USD Million)

11. North America Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. North America Drugs of Abuse Testing Market Size and Forecast By Product Type
11.2.1.1. XX Driving/Opportunity Factor
11.2.1.2. XX Driving/Opportunity Factor
11.3. North America Drugs of Abuse Testing Market Size and Forecast By Sample Type
11.3.1.1. XX Driving/Opportunity Factor
11.3.1.2. XX Driving/Opportunity Factor
11.4. North America Drugs of Abuse Testing Market Size and Forecast By Testing Type
11.4.1.1. XX Driving/Opportunity Factor
11.4.1.2. XX Driving/Opportunity Factor
11.5. North America Drugs of Abuse Testing Market Size and Forecast By Drug Type
11.5.1.1. XX Driving/Opportunity Factor
11.5.1.2. XX Driving/Opportunity Factor
11.6. North America Drugs of Abuse Testing Market Size and Forecast By Patient Demographics
11.6.1.1. XX Driving/Opportunity Factor
11.6.1.2. XX Driving/Opportunity Factor
11.7. North America Drugs of Abuse Testing Market Size and Forecast By End-User
11.7.1.1. XX Driving/Opportunity Factor
11.7.1.2. XX Driving/Opportunity Factor
11.8. North America Drugs of Abuse Testing Market Size and Forecast By Distribution Channel
11.8.1.1. XX Driving/Opportunity Factor
11.8.1.2. XX Driving/Opportunity Factor
11.9. U.S. Drugs of Abuse Testing Market
11.9.1.1. XX Driving/Opportunity Factor
11.9.1.2. XX Driving/Opportunity Factor
11.10. Canada Drugs of Abuse Testing Market
11.10.1.1. XX Driving/Opportunity Factor
11.10.1.2. XX Driving/Opportunity Factor

12. Europe Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. Europe Drugs of Abuse Testing Market Size and Forecast By Product Type
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. Europe Drugs of Abuse Testing Market Size and Forecast By Sample Type
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. Europe Drugs of Abuse Testing Market Size and Forecast By Testing Type
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. Europe Drugs of Abuse Testing Market Size and Forecast By Drug Type
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. Europe Drugs of Abuse Testing Market Size and Forecast By Patient Demographics
12.6.1.1. XX Driving/Opportunity Factor
12.6.1.2. XX Driving/Opportunity Factor
12.7. Europe Drugs of Abuse Testing Market Size and Forecast By End-User
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. Europe Drugs of Abuse Testing Market Size and Forecast By Distribution Channel
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
12.9. UK Drugs of Abuse Testing Market
12.9.1.1. XX Driving/Opportunity Factor
12.9.1.2. XX Driving/Opportunity Factor
12.10. Germany Drugs of Abuse Testing Market
12.10.1.1. XX Driving/Opportunity Factor
12.10.1.2. XX Driving/Opportunity Factor
12.11. France Drugs of Abuse Testing Market
12.11.1.1. XX Driving/Opportunity Factor
12.11.1.2. XX Driving/Opportunity Factor
12.12. Rest of Europe Drugs of Abuse Testing Market
12.12.1.1. XX Driving/Opportunity Factor
12.12.1.2. XX Driving/Opportunity Factor

13. Asia Pacific Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. Asia-Pacific Drugs of Abuse Testing Market Size and Forecast By Product Type
13.2.1.1. XX Driving/Opportunity Factor
13.2.1.2. XX Driving/Opportunity Factor
13.3. Asia-Pacific Drugs of Abuse Testing Market Size and Forecast By Sample Type
13.3.1.1. XX Driving/Opportunity Factor
13.3.1.2. XX Driving/Opportunity Factor
13.4. Asia-Pacific Drugs of Abuse Testing Market Size and Forecast By Drug Type
13.4.1.1. XX Driving/Opportunity Factor
13.4.1.2. XX Driving/Opportunity Factor
13.5. Asia-Pacific Drugs of Abuse Testing Market Size and Forecast By Testing Type
13.5.1.1. XX Driving/Opportunity Factor
13.5.1.2. XX Driving/Opportunity Factor
13.6. Asia-Pacific Drugs of Abuse Testing Market Size and Forecast By Patient Demographics
13.6.1.1. XX Driving/Opportunity Factor
13.6.1.2. XX Driving/Opportunity Factor
13.7. Asia-Pacific Drugs of Abuse Testing Market Size and Forecast By End-User
13.7.1.1. XX Driving/Opportunity Factor
13.7.1.2. XX Driving/Opportunity Factor
13.8. Asia-Pacific Drugs of Abuse Testing Market Size and Forecast By Distribution Channel
13.8.1.1. XX Driving/Opportunity Factor
13.8.1.2. XX Driving/Opportunity Factor
13.9. China Drugs of Abuse Testing Market
13.9.1.1. XX Driving/Opportunity Factor
13.9.1.2. XX Driving/Opportunity Factor
13.10. India Drugs of Abuse Testing Market
13.10.1.1. XX Driving/Opportunity Factor
13.10.1.2. XX Driving/Opportunity Factor
13.11. Japan Drugs of Abuse Testing Market
13.11.1.1. XX Driving/Opportunity Factor
13.11.1.2. XX Driving/Opportunity Factor
13.12. Rest of Asia Pacific Drugs of Abuse Testing Market
13.12.1.1. XX Driving/Opportunity Factor
13.12.1.2. XX Driving/Opportunity Factor

14. Latin America Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
14.1. Market Overview
14.2. Latin America Drugs of Abuse Testing Market Size and Forecast By Product Type
14.2.1.1. XX Driving/Opportunity Factor
14.2.1.2. XX Driving/Opportunity Factor
14.3. Latin America Drugs of Abuse Testing Market Size and Forecast By Sample Type
14.3.1.1. XX Driving/Opportunity Factor
14.3.1.2. XX Driving/Opportunity Factor
14.4. Latin America Drugs of Abuse Testing Market Size and Forecast By Drug Type
14.4.1.1. XX Driving/Opportunity Factor
14.4.1.2. XX Driving/Opportunity Factor
14.5. Latin America Drugs of Abuse Testing Market Size and Forecast By Testing Type
14.5.1.1. XX Driving/Opportunity Factor
14.5.1.2. XX Driving/Opportunity Factor
14.6. Latin America Drugs of Abuse Testing Market Size and Forecast By Patient Demographics
14.6.1.1. XX Driving/Opportunity Factor
14.6.1.2. XX Driving/Opportunity Factor
14.7. Latin America Drugs of Abuse Testing Market Size and Forecast By End-User
14.7.1.1. XX Driving/Opportunity Factor
14.7.1.2. XX Driving/Opportunity Factor
14.8. Latin America Drugs of Abuse Testing Market Size and Forecast By Distribution Channel
14.9. Brazil Drugs of Abuse Testing Market
14.9.1.1. XX Driving/Opportunity Factor
14.9.1.2. XX Driving/Opportunity Factor
14.10. Mexico Drugs of Abuse Testing Market
14.10.1.1. XX Driving/Opportunity Factor
14.10.1.2. XX Driving/Opportunity Factor
14.11. Rest of Latin America Drugs of Abuse Testing Market
14.11.1.1. XX Driving/Opportunity Factor
14.11.1.2. XX Driving/Opportunity Factor

15. MEA Drugs of Abuse Testing Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
15.1. Market Overview
15.2. MEA Drugs of Abuse Testing Market Size and Forecast By Product Type
15.2.1.1. XX Driving/Opportunity Factor
15.2.1.2. XX Driving/Opportunity Factor
15.3. MEA Drugs of Abuse Testing Market Size and Forecast By Sample Type
15.3.1.1. XX Driving/Opportunity Factor
15.3.1.2. XX Driving/Opportunity Factor
15.4. MEA Drugs of Abuse Testing Market Size and Forecast By Testing Type
15.4.1.1. XX Driving/Opportunity Factor
15.4.1.2. XX Driving/Opportunity Factor
15.5. MEA Drugs of Abuse Testing Market Size and Forecast By Drug Type
15.5.1.1. XX Driving/Opportunity Factor
15.5.1.2. XX Driving/Opportunity Factor
15.6. MEA Drugs of Abuse Testing Market Size and Forecast By Patient Demographics
15.6.1.1. XX Driving/Opportunity Factor
15.6.1.2. XX Driving/Opportunity Factor
15.7. MEA Drugs of Abuse Testing Market Size and Forecast By End-User
15.7.1.1. XX Driving/Opportunity Factor
15.7.1.2. XX Driving/Opportunity Factor
15.8. MEA Drugs of Abuse Testing Market Size and Forecast By Distribution Channel
15.8.1.1. XX Driving/Opportunity Factor
15.8.1.2. XX Driving/Opportunity Factor
15.9. GCC Drugs of Abuse Testing Market
15.9.1.1. XX Driving/Opportunity Factor
15.9.1.2. XX Driving/Opportunity Factor
15.10. South Africa Drugs of Abuse Testing Market
15.10.1.1. XX Driving/Opportunity Factor
15.10.1.2. XX Driving/Opportunity Factor
15.11. Rest of MEA Drugs of Abuse Testing Market
15.11.1.1. XX Driving/Opportunity Factor
15.11.1.2. XX Driving/Opportunity Factor

16. Companies in the Drugs of Abuse Testing Market
16.1. F. Hoffmann-La Roche AG
16.1.1. Company Snapshot
16.1.2. Company Overview
16.1.3. Financial Performance (2015-2019)
16.1.3.1. Net Revenue
16.1.3.2. Gross Profit
16.1.3.3. Geographical Revenue, 2019
16.1.4. Product Offerings
16.1.5. Recent Initiatives (2017-2019)
16.2. Siemens Healthineers (Siemens AG)
16.2.1. Company Snapshot
16.2.2. Company Overview
16.2.3. Financial Performance (2015-2019)
16.2.3.1. Net Revenue
16.2.3.2. Gross Profit
16.2.3.3. Geographical Revenue, 2019
16.2.4. Product Offerings
16.2.5. Recent Initiatives (2017-2019)
16.3. Thermo Fisher Scientific, Inc.
16.3.1. Company Snapshot
16.3.2. Company Overview
16.3.3. Financial Performance (2015-2019)
16.3.3.1. Net Revenue
16.3.3.2. Gross Profit
16.3.3.3. Geographical Revenue, 2019
16.3.4. Product Offerings
16.3.5. Recent Initiatives (2017-2019)
16.4. Abbott
16.4.1. Company Snapshot
16.4.2. Company Overview
16.4.3. Financial Performance (2015-2019)
16.4.3.1. Net Revenue
16.4.3.2. Gross Profit
16.4.3.3. Geographical Revenue, 2019
16.4.4. Product Offerings
16.4.5. Recent Initiatives (2017-2019)
16.5. Bio-Rad Laboratories Inc.
16.5.1. Company Snapshot
16.5.2. Company Overview
16.5.3. Financial Performance (2015-2019)
16.5.3.1. Net Revenue
16.5.3.2. Gross Profit
16.5.3.3. Geographical Revenue, 2019
16.5.4. Product Offerings
16.5.5. Recent Initiatives (2017-2019)
16.6. Drgerwerk ag & co. Kgaa
16.6.1. Company Snapshot
16.6.2. Company Overview
16.6.3. Financial Performance (2015-2019)
16.6.3.1. Net Revenue
16.6.3.2. Gross Profit
16.6.3.3. Geographical Revenue, 2019
16.6.4. Product Offerings
16.6.5. Recent Initiatives (2017-2019)
16.7. Shimadzu Corporation
16.7.1. Company Snapshot
16.7.2. Company Overview
16.7.3. Financial Performance (2015-2019)
16.7.3.1. Net Revenue
16.7.3.2. Gross Profit
16.7.3.3. Geographical Revenue, 2019
16.7.4. Product Offerings
16.7.5. Recent Initiatives (2017-2019)
16.8. Laboratory Corporation of America Holdings
16.8.1. Company Snapshot
16.8.2. Company Overview
16.8.3. Financial Performance (2015-2019)
16.8.3.1. Net Revenue
16.8.3.2. Gross Profit
16.8.3.3. Geographical Revenue, 2019
16.8.4. Product Offerings
16.8.5. Recent Initiatives (2017-2019)
16.9. Danaher
16.9.1. Company Snapshot
16.9.2. Company Overview
16.9.3. Financial Performance (2015-2019)
16.9.3.1. Net Revenue
16.9.3.2. Gross Profit
16.9.3.3. Geographical Revenue, 2019
16.9.4. Product Offerings
16.9.5. Recent Initiatives (2017-2019)
16.10. Express Diagnostics International, Inc.
16.10.1. Company Snapshot
16.10.2. Company Overview
16.10.3. Financial Performance (2015-2019)
16.10.3.1. Net Revenue
16.10.3.2. Gross Profit
16.10.3.3. Geographical Revenue, 2019
16.10.4. Product Offerings
16.10.5. Recent Initiatives (2017-2019)
16.11. Other Notable Players

17. Conclusion

18. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form

LIST OF TABLES
Table 1. Drugs of Abuse Testing Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Drugs of Abuse Testing Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Drugs of Abuse Testing Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Drugs of Abuse Testing Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Drugs of Abuse Testing Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Drugs of Abuse Testing Market Drivers & Restraints 2021
Table 7. Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 8. Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Analyzers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Analyzers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Analyzers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Analyzers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Analyzers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Rapid Testing Devices Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Rapid Testing Devices Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Rapid Testing Devices Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Rapid Testing Devices Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Rapid Testing Devices Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Consumables Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Consumables Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Consumables Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Consumables Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Consumables Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Laboratory Services Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Laboratory Services Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Laboratory Services Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Laboratory Services Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Laboratory Services Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Drugs of Abuse Testing Market Forecast By Sample Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Drugs of Abuse Testing Market Forecast By Sample Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Saliva Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Saliva Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Saliva Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Saliva Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Saliva Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Breath Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Breath Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Breath Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Breath Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Breath Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Urine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Urine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Urine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Urine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Urine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Blood Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Blood Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Blood Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Blood Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Blood Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Hair Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Hair Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Hair Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Hair Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Hair Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Sweat Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Sweat Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Sweat Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Sweat Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Sweat Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Alcohol Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Alcohol Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Alcohol Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Alcohol Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Alcohol Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Cannabis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Cannabis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Cannabis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Cannabis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Cannabis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Cocaine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Cocaine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Cocaine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Cocaine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Cocaine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Amphetamine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Amphetamine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Amphetamine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Amphetamine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Amphetamine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. LSD Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. LSD Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. LSD Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. LSD Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. LSD Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 108. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 113. Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 118. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 123. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 128. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 133. Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 138. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 142. Workplaces & Schools Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 143. Workplaces & Schools Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 144. Workplaces & Schools Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 145. Workplaces & Schools Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 146. Workplaces & Schools Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 148. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 152. Criminal Justice Systems & Law Enforcement Agencies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 153. Criminal Justice Systems & Law Enforcement Agencies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Criminal Justice Systems & Law Enforcement Agencies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Criminal Justice Systems & Law Enforcement Agencies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Criminal Justice Systems & Law Enforcement Agencies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 157. Diagnostics Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 158. Diagnostics Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 159. Diagnostics Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Diagnostics Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 161. Diagnostics Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 162. On-the-spot Testing Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 163. On-the-spot Testing Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 164. On-the-spot Testing Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 165. On-the-spot Testing Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 166. On-the-spot Testing Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 167. Forensic Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 168. Forensic Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Forensic Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 170. Forensic Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Forensic Laboratories Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 172. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 173. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 174. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 175. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 176. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 177. Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 178. Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 179. Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 180. Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 181. Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 182. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 183. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 184. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 185. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 186. Direct Tender Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 187. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 188. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 189. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 190. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 191. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 192. North America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193. North America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. North America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. North America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. North America Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197. North America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198. North America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199. North America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200. North America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201. North America Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202. North America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203. North America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204. North America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205. North America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206. North America Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207. North America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208. North America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209. North America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210. North America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211. North America Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212. North America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213. North America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214. North America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215. North America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216. North America Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217. North America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 218. North America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 219. North America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 220. North America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 221. North America Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 222. North America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 223. North America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 224. North America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 225. North America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 226. North America Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 227. North America Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 228. North America Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 229. North America Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 230. North America Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 231. North America Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 232. US Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 233. US Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 234. US Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 235. US Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 236. US Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 237. Canada Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 238. Canada Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 239. Canada Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 240. Canada Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 241. Canada Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 242. Europe Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 243. Europe Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 244. Europe Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 245. Europe Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 246. Europe Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 247. Europe Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 248. Europe Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 249. Europe Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 250. Europe Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 251. Europe Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 252. Europe Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 253. Europe Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 254. Europe Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 255. Europe Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 256. Europe Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 257. Europe Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 258. Europe Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 259. Europe Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 260. Europe Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 261. Europe Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 262. Europe Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 263. Europe Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 264. Europe Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 265. Europe Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 266. Europe Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 267. Europe Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 268. Europe Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 269. Europe Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 270. Europe Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 271. Europe Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 272. Europe Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 273. Europe Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 274. Europe Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 275. Europe Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 276. Europe Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 277. Europe Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 278. Europe Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 279. Europe Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 280. Europe Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 281. Europe Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 282. UK Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 283. UK Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 284. UK Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 285. UK Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 286. UK Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 287. Germany Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 288. Germany Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 289. Germany Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 290. Germany Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 291. Germany Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 292. France Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 293. France Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 294. France Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 295. France Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 296. France Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 297. Rest of Europe Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 298. Rest of Europe Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 299. Rest of Europe Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 300. Rest of Europe Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 301. Rest of Europe Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 302. Asia Pacific Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 303. Asia Pacific Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 304. Asia Pacific Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 305. Asia Pacific Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 306. Asia Pacific Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 307. Asia Pacific Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 308. Asia Pacific Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 309. Asia Pacific Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 310. Asia Pacific Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 311. Asia Pacific Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 312. Asia Pacific Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 313. Asia Pacific Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 314. Asia Pacific Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 315. Asia Pacific Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 316. Asia Pacific Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 317. Asia Pacific Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 318. Asia Pacific Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 319. Asia Pacific Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 320. Asia Pacific Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 321. Asia Pacific Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 322. Asia Pacific Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 323. Asia Pacific Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 324. Asia Pacific Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 325. Asia Pacific Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 326. Asia Pacific Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 327. Asia Pacific Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 328. Asia Pacific Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 329. Asia Pacific Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 330. Asia Pacific Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 331. Asia Pacific Drugs of Abuse Testing Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 332. Asia Pacific Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 333. Asia Pacific Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 334. Asia Pacific Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 335. Asia Pacific Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 336. Asia Pacific Drugs of Abuse Testing Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 337. Asia Pacific Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 338. Asia Pacific Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 339. Asia Pacific Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 340. Asia Pacific Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 341. Asia Pacific Drugs of Abuse Testing Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 342. China Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 343. China Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 344. China Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 345. China Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 346. China Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 347. India Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 348. India Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 349. India Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 350. India Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 351. India Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 352. Japan Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 353. Japan Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 354. Japan Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 355. Japan Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 356. Japan Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 357. RoAPAC Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 358. RoAPAC Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 359. RoAPAC Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 360. RoAPAC Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 361. RoAPAC Drugs of Abuse Testing Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 362. Middle East Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 363. Middle East Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 364. Middle East Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 365. Middle East Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 366. Middle East Drugs of Abuse Testing Market Forecast By Product Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 367. Middle East Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 368. Middle East Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 369. Middle East Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 370. Middle East Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 371. Middle East Drugs of Abuse Testing Market Forecast By Sample Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 372. Middle East Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 373. Middle East Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 374. Middle East Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 375. Middle East Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 376. Middle East Drugs of Abuse Testing Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 377. Middle East Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 378. Middle East Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 379. Middle East Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 380. Middle East Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 381. Middle East Drugs of Abuse Testing Market Forecast By Testing Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 382. Middle East Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 383. Middle East Drugs of Abuse Testing Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, C

この商品のレポートナンバー

0000028536

TOP